Ligand Pharmaceuticals LGND
$286.85 −$0.09 (-0.03%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $286.85 0.00%
Open$285.21
Prev close$286.94
Day range$282.36 – $291.36
Volume259.8K
Market cap$5.74B
P/E (TTM)115.2
Dividend yield–
LGND Stock News
Headlines matching Ligand Pharmaceuticals or the LGND ticker, most recent first.
- Barclays Initiates Ligand Pharmaceuticals(LGND.US) With Buy Rating, Announces Target Price $345
- Citi Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $397
- H.C. Wainwright Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $358
- Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating
- A Quick Look at Today's Ratings for Ligand Pharmaceuticals(LGND.US), With a Forecast Between $388 to $397
- A Quick Look at Today's Ratings for Ligand Pharmaceuticals(LGND.US), With a Forecast Between $326 to $370
- RBC Capital Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $345 Positive
- H.C. Wainwright Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $358 Positive
- Oppenheimer Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $326 Positive
- Stifel Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $332
- Citi Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $390 Positive
- RBC Capital Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $345
- BofA Securities Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $388 Positive
- Stifel Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $332 Positive
- BofA Securities Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $388
No comments yet — be the first to weigh in on LGND.
Sign in to join the discussion.